Tenax Therapeut Stock
StockStockPrice
Frequently asked questions
What is Tenax Therapeut's market capitalization?
What is the Earnings Per Share (EPS) for Tenax Therapeut?
What are the analyst ratings and target price for Tenax Therapeut's stock?
What is the EBITDA for Tenax Therapeut?
What is the free cash flow of Tenax Therapeut?
What is the 5-year beta of Tenax Therapeut's stock?
How many employees does Tenax Therapeut have, and what sector and industry does it belong to?
What is the free float of Tenax Therapeut's shares?
Financials
Market Cap
$16.19M5Y beta
2.17EPS (TTM)
-$22.35Free Float
3.40MEBITDA (TTM)
-$13.03MFree Cashflow (TTM)
-$11.45MPricing
Analyst Ratings
The price target is $32.50 and the stock is covered by 1 analysts.
Buy
1
Hold
0
Sell
0
Information
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 (IV), TNX-102 (subcutaneous) and TNX-103 (oral) levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
5
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker